Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Chief Legal Officer | June 27, 2024 | June 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date June 27, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,484 |
Ending reported balance
After 2024-06-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-27 · Exercise / conversion · Acquired 6,424 · Balance 16,424 Row 2 · 2024-06-27 · Exercise / conversion · Acquired 47,060 · Balance 63,484 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.34 · Expires 2030-06-30 | Direct | 41,186 |
Reported balance
After 2024-06-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-27 · Exercise / conversion · Disposed 6,424 · Balance 41,186 F1: 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2029-10-08 | Direct | 1,360 |
Reported balance
After 2024-06-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-27 · Exercise / conversion · Disposed 47,060 · Balance 1,360 F2: The shares subject to the option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F2: The shares subject to the option are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2021 Filed Jul 8, 2021 23:00 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 6,468 | $22.16 | $143,357.40 |
DisclosureSEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 3 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,532 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.56 to $22.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:00 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 2,390 | $13.34 | $31,882.60 |
DisclosureSEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 2 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:00 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 7,610 | $7.01 | $53,346.10 |
DisclosureSEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 1 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:09 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $19.52 | $0.00 |
DisclosureSEC source: 0001567619-21-005113 · doc1.xml · derivative · entry 1 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 1,579 | $15.55 | $24,548.24 |
DisclosureSEC source: 0001567619-20-020759 · doc1.xml · nonDerivative · entry 2 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades in prices ranging from $15.39 to $15.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,979 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 400 | $14.66 | $5,862.00 |
DisclosureSEC source: 0001567619-20-020759 · doc1.xml · nonDerivative · entry 1 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,579 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $14.38 to $15.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,979 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:44 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $13.34 | $0.00 |
DisclosureSEC source: 0001567619-20-012887 · doc1.xml · derivative · entry 1 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:51 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,205 | $8.66 | $19,086.70 |
DisclosureSEC source: 0001567619-20-011852 · doc1.xml · nonDerivative · entry 1 Throne Jason · CIK 0001790865 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $8.40 to $8.78, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 2,205 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 16:46 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001567619-19-019494 · doc1.xml · derivative · entry 1 Throne Jason · CIK 0001790865 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-10-08 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from October 9, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.